Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5546911 | Actualités Pharmaceutiques | 2016 | 10 Pages |
Abstract
Tricyclic antidepressants were, along with imipramine and amitriptyline, the first molecules created to treat depression. More recently, serotonin reuptake inhibitors have developed significantly. Their efficacy is similar to that of tricyclics, with greater tolerance. The indications of these drugs have extended to conditions other than depression. The challenge is now to differentiate between them and attempt to identify more or less specific profiles.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
Nathalie (Maître de conférence), Nelly (Maître de conférence, praticien hospitalier), Sébastien (Professeur des Universités),